Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis.
Fiche publication
Date publication
octobre 2022
Journal
European journal of cancer care
Auteurs
Membres identifiés du Cancéropôle Est :
Dr KROEMER Marie
Tous les auteurs :
Zerbit J, Kroemer M, Fuchs B, Detroit M, Decroocq J, Vignon M, Willems L, Deau-Fischer B, Franchi P, Deschamps P, Contejean A, Grignano E, Fouquet G, Birsen R, Mondesir J, Rocquet M, Huon JF, Batista R, Marty-Reboul J, Bouscary D
Lien Pubmed
Résumé
The clinical benefit of pharmaceutical cares in improving the quality-of-care outcomes is well demonstrated. Clinical pharmacy services are not systematically deployed in cancer units in the absence of economic data. The aim of this prospective, observational 1-year study was to evaluate the clinical, economic and organisational impacts of pharmaceutical care into a multidisciplinary day hospital for patients treated with oral cancer drugs.
Mots clés
blood cancers, economic, leukaemia, lymphoma, myeloma, pharmacist
Référence
Eur J Cancer Care (Engl). 2022 10 23;:e13753